Chronic angina may persist even after percutaneous coronary intervention (PCI).
Patients with PCI admissions between 2008-2011 were identified from the Truven Health MarketScan® Commercial and the Medicare Supplemental Research claims databases. Angina or chest pain post-PCI was ascertained using medical diagnosis and procedure codes. Patients were followed up for 36 months.
ARTS, COURAGE, SYNTAX, FAME, AND BARI-2D trials†2-6
Baseline data represent the percentage of patients reporting angina at study baseline.
The BARI-2D trial enrolled patients with coronary artery disease, type 2 diabetes mellitus, and myocardial ischemia. This reflects a subset of patients with classic angina.
ARTS=Arterial Revascularization Therapies Study;
BARI-2D=Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes Trial;
COURAGE=Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Trial;
FAME=Fractional Flow Reserve Versus Angiography for Multivessel Evaluation;
SYNTAX=Synergy Between PCI With Taxus and Cardiac Surgery Trial.
Understand available dosing and recommendations regarding titration, as well as important treatment considerations.See Dosing Information
Learn about safety data from the Ranexa clinical trials, including use in special populations.Review Safety & Tolerability
Ranexa Connect™ is a financial assistance resource for patients with a Ranexa prescription.
Ranexa Connect is pleased to announce iAssist, a program to help get your patients started on Ranexa faster. The program offers online patient enrollment, electronic signatures, as well as real-time pharmacy benefit check and eligibility for financial assistance.Get Started Now